By Adriano Marchese
Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in survival.
The clinical-stage immuno-oncology company said Tuesday that it won't continue to final analysis and cease development of nemvaleukin, its drug that was aimed to treat platinum-resistant ovarian cancer.
This particular ovarian cancer is resistant to platinum-based chemotherapy treatments which are commonly the first option.
Mural Oncology said the Artistry-7 phase 3 trial of nemvaleukin alfa in combination with Merck's anti-PD-1 therapy, Keytruda, didn't achieve a statistically significant improvement in overall survival compared with chemotherapy alone.
Shares of Mural were over 26% lower in premarket trading at $2.82.
The treatment is still being evaluated in a phase 2 trial to treat mucosal melanoma. The company said it expects to share its data readout in the second quarter.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 25, 2025 07:08 ET (11:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。